CLINUVEL PHARMACEUTICALS LTD (ASX: CUV), a global biopharmaceutical company focused on developing and delivering innovative therapies for patients with genetic, metabolic, and dermatological disorders, has announced its tenth consecutive annual profit for the financial year ended 30 June 2026 (FY2026). The company’s portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. This sustained profitability, coupled with a further rise in free cash, provides a robust foundation for CLINUVEL’s strategic expansion in the United States, as the firm declared a dividend of $0.05 per ordinary share.
The Melbourne-based company reported revenues from ordinary activities of $94.024 million, a marginal 1% decrease year-on-year. Total revenues, including interest and other income, stood at $101.153 million, down 4%. Expenses were tightly controlled, declining by 0.5% to $53.493 million. Despite record SCENESSE® treatment volumes, net profit before income tax expense saw an 8% dip to $47.660 million. This was primarily attributed to the accounting treatment of unrealised foreign currency losses on US dollar term deposit balances, while net profit after tax declined 6% to $33.917 million.
CLINUVEL’s financial discipline was underscored by a significant 12% increase in cash reserves, reaching $252.055 million at year-end. Group Chief Financial Officer Mr Peter Vaughan noted these strong cash reserves provide the company with financial independence to pursue its expansion strategy and invest in key strategic areas. The strengthened balance sheet, boasting net assets of $272.9 million, positions CLINUVEL to self-finance its diversification plans with an emphasis on North American growth. The Board’s declaration of a ninth consecutive annual dividend of $0.05 per ordinary share further reflects this stable financial performance.
